Literature DB >> 7061695

Melatonin serum levels and metabolic clearance rate in patients with liver cirrhosis.

H Iguchi, K I Kato, H Ibayashi.   

Abstract

To evaluate the influence of changes in liver function on serum levels of melatonin, we measured serum levels and MCR of the hormone in patients with liver cirrhosis and in healthy control subjects. Daytime (0900-1100 h) serum levels of melatonin in patients with liver cirrhosis were significantly elevated compared to those in healthy subjects. Significant positive correlations of the daytime serum levels of melatonin with the serum retention rate of indocyanine green dye and serum levels of total bilirubin were noted. The clearance of melatonin from blood showed a biphasic first-order kinetic pattern. The half-life of each phase was significantly prolonged in patients with cirrhosis compared to healthy subjects. Our data indicate that the elevated daytime serum levels of melatonin in patients with liver cirrhosis are due to decreased clearance, probably related to decreased liver blood flow, lowered activity of 6 beta-hydroxylase, and competition with bilirubin in the intrahepatic transport system.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7061695     DOI: 10.1210/jcem-54-5-1025

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  24 in total

Review 1.  Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Authors:  Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

Review 2.  Contribution of altered signal transduction associated to glutamate receptors in brain to the neurological alterations of hepatic encephalopathy.

Authors:  Vicente Felipo
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

Review 3.  Melatonin and its receptors: a new class of sleep-promoting agents.

Authors:  Karl Doghramji
Journal:  J Clin Sleep Med       Date:  2007-08-15       Impact factor: 4.062

4.  A physiologically based mathematical model of melatonin including ocular light suppression and interactions with the circadian pacemaker.

Authors:  Melissa A St Hilaire; Claude Gronfier; Jamie M Zeitzer; Elizabeth B Klerman
Journal:  J Pineal Res       Date:  2007-10       Impact factor: 13.007

Review 5.  Circadian rhythm sleep disorders: pathophysiology and potential approaches to management.

Authors:  N Zisapel
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

6.  Estimation of time of death by quantification of melatonin in corpses.

Authors:  H Mikami; K Terazawa; T Takatori; S Tokudome; T Tsukamoto; K Haga
Journal:  Int J Legal Med       Date:  1994       Impact factor: 2.686

7.  Pharmacokinetics of melatonin in man after intravenous infusion and bolus injection.

Authors:  C Mallo; R Zaĭdan; G Galy; E Vermeulen; J Brun; G Chazot; B Claustrat
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

8.  De novo discovery of serotonin N-acetyltransferase inhibitors.

Authors:  Lawrence M Szewczuk; S Adrian Saldanha; Surajit Ganguly; Erin M Bowers; Margarita Javoroncov; Balasubramanyam Karanam; Jeffrey C Culhane; Marc A Holbert; David C Klein; Ruben Abagyan; Philip A Cole
Journal:  J Med Chem       Date:  2007-10-09       Impact factor: 7.446

9.  Urine melatonin in alcoholic patients: a marker of alcohol abuse?

Authors:  G Murialdo; U Filippi; P Costelli; S Fonzi; P Bo; A Polleri; F Savoldi
Journal:  J Endocrinol Invest       Date:  1991-06       Impact factor: 4.256

10.  Chronotypology and melatonin alterations in minimal hepatic encephalopathy.

Authors:  Dimitrios Velissaris; Vasilis Karamouzos; Panagiotis Polychronopoulos; Menelaos Karanikolas
Journal:  J Circadian Rhythms       Date:  2009-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.